136 related articles for article (PubMed ID: 31433065)
1. Antitumor effect of insulin-like growth factor-1 receptor inhibition in head and neck squamous cell carcinoma.
Lehman CE; Khalil AA; Axelrod MJ; Dougherty MI; Schoeff SS; Taniguchi LE; Mendez RE; David AP; McGarey PO; Hubbard MA; Donaldson L; Frierson HF; Stelow EB; Bekiranov S; Wulfkuhle JD; Petricoin EF; Gioeli DG; Jameson MJ
Laryngoscope; 2020 Jun; 130(6):1470-1478. PubMed ID: 31433065
[TBL] [Abstract][Full Text] [Related]
2. IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK.
Lehman CE; Spencer A; Hall S; Shaw JJP; Wulfkuhle J; Petricoin EF; Bekiranov S; Jameson MJ; Gioeli D
Sci Rep; 2021 May; 11(1):10826. PubMed ID: 34031486
[TBL] [Abstract][Full Text] [Related]
3. PRAS40 Phosphorylation Correlates with Insulin-Like Growth Factor-1 Receptor-Induced Resistance to Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Dougherty MI; Lehman CE; Spencer A; Mendez RE; David AP; Taniguchi LE; Wulfkuhle J; Petricoin EF; Gioeli D; Jameson MJ
Mol Cancer Res; 2020 Sep; 18(9):1392-1401. PubMed ID: 32467173
[TBL] [Abstract][Full Text] [Related]
4. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.
Jameson MJ; Beckler AD; Taniguchi LE; Allak A; Vanwagner LB; Lee NG; Thomsen WC; Hubbard MA; Thomas CY
Mol Cancer Ther; 2011 Nov; 10(11):2124-34. PubMed ID: 21878657
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of IGF1R Expression Inhibits Growth and Enhances Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cells In Vitro.
Khalil A; Jameson MJ
Horm Cancer; 2019 Feb; 10(1):11-23. PubMed ID: 30350263
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma.
Kramer B; Schell A; Aderhold C; Huber L; Mueller CE; Rotter N; Birk R
Anticancer Res; 2020 Jul; 40(7):3847-3855. PubMed ID: 32620624
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer.
Liu F; Liu Y; Liu X; Mao K; Zhong D; Marcus AI; Khuri FR; Sun SY; He Y; Zhou W
Lung Cancer; 2018 Sep; 123():36-43. PubMed ID: 30089593
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
[TBL] [Abstract][Full Text] [Related]
9. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
Cassell A; Freilino ML; Lee J; Barr S; Wang L; Panahandeh MC; Thomas SM; Grandis JR
Neoplasia; 2012 Nov; 14(11):1005-14. PubMed ID: 23226094
[TBL] [Abstract][Full Text] [Related]
10. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
11. Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas.
Tepper SR; Zuo Z; Khattri A; Heß J; Seiwert TY
Oral Oncol; 2016 May; 56():62-70. PubMed ID: 27086488
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
13. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
[TBL] [Abstract][Full Text] [Related]
14. Impact of targeting insulin-like growth factor signaling in head and neck cancers.
Limesand KH; Chibly AM; Fribley A
Growth Horm IGF Res; 2013 Oct; 23(5):135-40. PubMed ID: 23816396
[TBL] [Abstract][Full Text] [Related]
15. Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells.
Jameson MJ; Taniguchi LE; VanKoevering KK; Stuart MM; Francom CR; Mendez RE; Beckler AD; Carlson HT; Thomas CY; Khalil AA
J Oral Pathol Med; 2013 Apr; 42(4):332-8. PubMed ID: 23106397
[TBL] [Abstract][Full Text] [Related]
16. Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways.
Axelrod MJ; Mendez RE; Khalil A; Leimgruber SS; Sharlow ER; Capaldo B; Conaway M; Gioeli DG; Weber MJ; Jameson MJ
Head Neck; 2015 Dec; 37(12):1722-32. PubMed ID: 24986420
[TBL] [Abstract][Full Text] [Related]
17. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
18. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
[TBL] [Abstract][Full Text] [Related]
19. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.
Rodrigues Alves APN; Fernandes JC; Fenerich BA; Coelho-Silva JL; Scheucher PS; Simões BP; Rego EM; Ridley AJ; Machado-Neto JA; Traina F
Cancer Lett; 2019 Aug; 456():59-68. PubMed ID: 31042587
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting IGF1R-mediated Survival Signaling in Head and Neck Cancer with the Peptidomimetic SSTN
Stueven NA; Beauvais DM; Hu R; Kimple RJ; Rapraeger AC
Cancer Res Commun; 2023 Jan; 3(1):97-108. PubMed ID: 36968227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
